# Open-label Safety Study in Adults With ADHD

> **NCT02160262** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 724 (actual)

## Conditions studied

- Adult Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Dasotraline

## Key facts

- **NCT ID:** NCT02160262
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 724 (ACTUAL)
- **Last updated:** 2017-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02160262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02160262, "Open-label Safety Study in Adults With ADHD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02160262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*